tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jami Rubin, 48 are a BUY (54.55%), 27 are a HOLD (30.68%), 13 are a SELL (14.77%).
Analyst Jami Rubin, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 77.63% that have a potential upside of 41% achieved within 820 days. Previously, Jami Rubin worked at MORGAN STANLEY.
Jami Rubin’s has documented 174 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 15-Oct-2018.
Analyst best performing recommendations are on ZTS (ZOETIS).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 12/15/2017. The price target of $20 was fulfilled within 26 days with a profit of $1.39 (7.47%) receiving and performance score of 2.87.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 04-Feb-2020
$288
$11.53 (4.17%)
$288
Hold Since 06-Jan-2026
$275
$-1.47 (-0.53%)
$260
Buy Since 15-Oct-2020
$300
$23.53 (8.51%)
$280
Buy Since 15-Nov-2023
$290
$13.53 (4.89%)
$285
Buy Since 05-Apr-2022
$310
$33.53 (12.13%)
$278
6 days ago
(06-Oct-2026)
32/34 (94.12%)
$38.64 (14.24%)
496
What Year was the first public recommendation made by Jami Rubin?
